Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial.
Anti-inflammatory agent
Antioxidants
Non-alcoholic fatty liver disease
Oxidative stress
Tocotrienols
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
received:
16
02
2024
accepted:
05
08
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
19
8
2024
Statut:
epublish
Résumé
Childhood obesity is a growing concern, and non-alcoholic fatty liver disease (NAFLD) is a significant consequence. Currently, there are no approved drugs to treat NAFLD in children. However, a recent study explored the potential of vitamin E enriched with tocotrienol (TRF) as a powerful antioxidant for NAFLD. The aims of the present study were to investigate the effectiveness and safety of TRF in managing children with obesity and NAFLD. A total of 29 patients aged 10 to 18 received a daily oral dose of 50 mg TRF for six months (January 2020 to February 2022), and all had fatty liver disease were detected by ultrasonography and abnormally high alanine transaminase levels (at least two-fold higher than the upper limits for their respective genders). Various parameters, including biochemical markers, FibroScan, LiverFASt, DNA damage, and cytokine expression, were monitored. APO-A1 and AST levels decreased significantly from 1.39 ± 0.3 to 1.22 ± 0.2 g/L (P = 0.002) and from 30 ± 12 to 22 ± 10 g/L (P = 0.038), respectively, in the TRF group post-intervention. Hepatic steatosis was significantly reduced in the placebo group from 309.38 ± 53.60 db/m to 277.62 ± 39.55 db/m (p = 0.048), but not in the TRF group. Comet assay analysis showed a significant reduction in the DNA damage parameters in the TRF group in the post-intervention period compared to the baseline, with tail length decreasing from 28.34 ± 10.9 to 21.69 ± 9.84; (p = 0.049) and with tail DNA (%) decreasing from 54.13 ± 22.1to 46.23 ± 17.9; (p = 0.043). Pro-inflammatory cytokine expression levels were significantly lower in the TRF group compared to baseline levels for IL-6 (2.10 6.3 to 0.7 1.0 pg/mL; p = 0.047 pg/mL) and TNF-1 (1.73 5.5 pg/mL to 0.7 0.5 pg/mL; p = 0.045). The study provides evidence that TRF supplementation may offer a risk-free treatment option for children with obesity and NAFLD. The antioxidant and anti-inflammatory properties of TRF offer a promising adjuvant therapy for NAFLD treatment. In combination with lifestyle modifications such as exercise and calorie restriction, TRF could play an essential role in the prevention of NAFLD in the future. However, further studies are needed to explore the long-term effects of TRF supplementation on NAFLD in children. The study has been registered with the International Clinical Trial Registry under reference number (NCT05905185) retrospective registration on (15/06/2023).
Sections du résumé
BACKGROUND
BACKGROUND
Childhood obesity is a growing concern, and non-alcoholic fatty liver disease (NAFLD) is a significant consequence. Currently, there are no approved drugs to treat NAFLD in children. However, a recent study explored the potential of vitamin E enriched with tocotrienol (TRF) as a powerful antioxidant for NAFLD. The aims of the present study were to investigate the effectiveness and safety of TRF in managing children with obesity and NAFLD.
METHODS
METHODS
A total of 29 patients aged 10 to 18 received a daily oral dose of 50 mg TRF for six months (January 2020 to February 2022), and all had fatty liver disease were detected by ultrasonography and abnormally high alanine transaminase levels (at least two-fold higher than the upper limits for their respective genders). Various parameters, including biochemical markers, FibroScan, LiverFASt, DNA damage, and cytokine expression, were monitored.
RESULTS
RESULTS
APO-A1 and AST levels decreased significantly from 1.39 ± 0.3 to 1.22 ± 0.2 g/L (P = 0.002) and from 30 ± 12 to 22 ± 10 g/L (P = 0.038), respectively, in the TRF group post-intervention. Hepatic steatosis was significantly reduced in the placebo group from 309.38 ± 53.60 db/m to 277.62 ± 39.55 db/m (p = 0.048), but not in the TRF group. Comet assay analysis showed a significant reduction in the DNA damage parameters in the TRF group in the post-intervention period compared to the baseline, with tail length decreasing from 28.34 ± 10.9 to 21.69 ± 9.84; (p = 0.049) and with tail DNA (%) decreasing from 54.13 ± 22.1to 46.23 ± 17.9; (p = 0.043). Pro-inflammatory cytokine expression levels were significantly lower in the TRF group compared to baseline levels for IL-6 (2.10 6.3 to 0.7 1.0 pg/mL; p = 0.047 pg/mL) and TNF-1 (1.73 5.5 pg/mL to 0.7 0.5 pg/mL; p = 0.045).
CONCLUSION
CONCLUSIONS
The study provides evidence that TRF supplementation may offer a risk-free treatment option for children with obesity and NAFLD. The antioxidant and anti-inflammatory properties of TRF offer a promising adjuvant therapy for NAFLD treatment. In combination with lifestyle modifications such as exercise and calorie restriction, TRF could play an essential role in the prevention of NAFLD in the future. However, further studies are needed to explore the long-term effects of TRF supplementation on NAFLD in children.
TRIAL REGISTRATION
BACKGROUND
The study has been registered with the International Clinical Trial Registry under reference number (NCT05905185) retrospective registration on (15/06/2023).
Identifiants
pubmed: 39160468
doi: 10.1186/s12887-024-04993-8
pii: 10.1186/s12887-024-04993-8
doi:
Substances chimiques
Tocotrienols
0
Antioxidants
0
Vitamin E
1406-18-4
Banques de données
ClinicalTrials.gov
['NCT05905185']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
529Informations de copyright
© 2024. The Author(s).
Références
Marcinkiewicz K, Horodnicka-Józwa A, Jackowski T, Strączek K, Biczysko-Mokosa A, Walczak M, Petriczko E. Nonalcoholic fatty liver disease in children with obesity–observations from one clinical centre in the Western Pomerania region. Front Endocrinol. 2022;13: 992264.
Phen C, Ramirez CM. Hepatic steatosis in the pediatric population: an overview of pathophysiology, genetics, and diagnostic workup. Clin Liver Dis. 2021;17(3):191.
Peng L, Wu S, Zhou N, Zhu S, Liu Q, Li X. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. BMC Pediatr. 2021;21(1):1–8.
Ranucci G, Spagnuolo MI, Iorio R. Obese children with fatty liver: between reality and disease mongering. World J Gastroenterol. 2017;23(47): 8277.
pubmed: 29307987
pmcid: 5743498
Li J, Ren W. Diagnosis and therapeutic strategies for non-alcoholic fatty liver disease in children. Zhonghua gan Zang Bing za zhi= Zhonghua Ganzangbing Zazhi= Chinese. J Hepatol. 2020;28(3):208–12.
Mann JP, Valenti L, Scorletti E, Byrne CD, Nobili V: Nonalcoholic fatty liver disease in children. In: Seminars in liver disease: 2018: Thieme Medical Publishers; 2018: 001–013.
UNICEF. The State of the World’s Children 2019. Children, Food and Nutrition: Growing well in a changing world. New York: UNICEF; 2019.
Mohamed RZ, Jalaludin MY, Zaini AA. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity. J Pediatr Endocrinol Metab. 2020;33(2):247–53.
pubmed: 31926095
Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919–28.
pubmed: 37845512
pmcid: 10667098
Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology. 2020;158(7):1967–83 e1961.
pubmed: 32201176
Al-Baiaty FD, Ismail A, Abdul Latiff Z, Muhammad Nawawi KN, Raja Ali RA, Mokhtar NM. Possible hepatoprotective effect of tocotrienol-rich fraction vitamin E in non-alcoholic fatty liver disease in obese children and adolescents. Front Pediatr. 2021;9:667247.
pubmed: 34307250
pmcid: 8295474
Ratziu V, Friedman SL. Why do so many NASH trials fail? Gastroenterology. 2020;S0016–5085(0020):30680.
Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, Rinaldi L, Marfella R, Sasso FC. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24(2): 1703.
pubmed: 36675217
pmcid: 9865319
Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The role of vitamin E in the treatment of NAFLD. Diseases. 2018;6(4): 86.
pubmed: 30249972
pmcid: 6313719
Alberti G, Gana JC, Santos JL. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. Nutrients. 2020;12(11): 3531.
pubmed: 33212947
pmcid: 7698421
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328–57.
pubmed: 28714183
Pervez MA, Khan DA, Slehria AUR, Ijaz A. Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Complement Ther Med. 2020;52: 102494.
pubmed: 32951743
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–62.
pubmed: 35569886
Elizabeth LY, Schwimmer JB. Epidemiology of pediatric nonalcoholic fatty liver disease. Clinical Liver Disease. 2021;17(3):196–9.
Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB. Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease. J Pediatr. 2018;198(76–83): e72.
Gama A, Rosado-Marques V, Machado-Rodrigues AM, Nogueira H, Mourao I, Padez C. Prevalence of overweight and obesity in 3-to-10-year-old children: assessment of different cut-off criteria WHO-IOTF. An Acad Bras Ciênc. 2020;92: e20190449.
pubmed: 32785443
Ene-Obong H, Ibeanu V, Onuoha N, Ejekwu A. Prevalence of overweight, obesity, and thinness among urban school-aged children and adolescents in southern Nigeria. Food Nutr Bull. 2012;33(4):242–50.
pubmed: 23424890
Ismail IS, Bebakar W, Kamaruddin N, Abdullah N, Zin F, Taib S. Clinical practice guidelines on management of obesity. Putrajaya: Ministry of Health Malaysia, Academy of Medicine of Malaysia, Malaysian Association for the Study of Obesity, Malaysian Endocrine and Metabolic Society; 2004.
Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9: 1290.
pubmed: 30524276
pmcid: 6256123
Castro-Mejia JL, Khakimov B, Krych L, Bulow J, Bechshoft RL, Hojfeldt G, Mertz KH, Garne ES, Schacht SR, Ahmad HF, et al. Physical fitness in community-dwelling older adults is linked to dietary intake, gut microbiota, and metabolomic signatures. Aging Cell. 2020;19(3): e13105.
pubmed: 31967716
pmcid: 7059135
Boursier J, Guillaume M, Leroy V, Irlès M, Roux M, Lannes A, Foucher J, Zuberbuhler F, Delabaudière C, Barthelon J. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019;71(2):389–96.
pubmed: 31102719
Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, Team LSR. FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis. J Clin Med. 2021;10(11): 2415.
Chan WK, Nik Mustapha NR, Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2014;29(7):1470–6.
pubmed: 24548002
Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184–91.
pubmed: 3345800
Bankoglu EE, Seyfried F, Arnold C, Soliman A, Jurowich C, Germer CT, Otto C, Stopper H. Reduction of DNA damage in peripheral lymphocytes of obese patients after bariatric surgery-mediated weight loss. Mutagenesis. 2018;33(1):61–7.
pubmed: 29294093
Magenis ML, Damiani AP, de Marcos PS, de Pieri E, de Souza E, Vilela TC, de Andrade VM. Fructose consumption during pregnancy and lactation causes DNA damage and biochemical changes in female mice. Mutagenesis. 2020;35(2):179–87.
pubmed: 31967303
Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117(5):662–8.
pubmed: 28345499
Zhao L, Fang X, Marshall MR, Chung S. Regulation of obesity and metabolic complications by gamma and delta tocotrienols. Molecules. 2016;21(3):344.
pubmed: 26978344
pmcid: 6274282
Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV, Garofalo C, Moine Q, Desjardins Y, Levy E, et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut. 2015;64(6):872–83.
pubmed: 25080446
Napolitano G, Fasciolo G, Di Meo S, Venditti P. Vitamin E supplementation and mitochondria in experimental and functional hyperthyroidism: a mini-review. Nutrients. 2019;11(12): 2900.
pubmed: 31805673
pmcid: 6950234
J Majima H, P Indo H, Suenaga S, Matsui H, Yen HC, Ozawa T. Mitochondria as possible pharmaceutical targets for the effects of vitamin E and its homologues in oxidative stress-related diseases. Curr Pharm Des. 2011;17(21):2190-2195.
Goon JA, Azman NHEN, Ghani SMA, Hamid Z, Ngah WZW. Comparing palm oil tocotrienol rich fraction with α-tocopherol supplementation on oxidative stress in healthy older adults. Clin Nutr ESPEN. 2017;21:1–12.
pubmed: 30014863
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–80.
pubmed: 21508958
pmcid: 3728647
Qureshi A, Khan D, Mahjabeen W, Trias A, Silswal N, Qureshi N. Impact of δ-tocotrienol on inflammatory biomarkers and oxidative stress in hypercholesterolemic subjects. J Clin Exp Cardiolog. 2015;6(367):2.
Godoy-Matos AF, Júnior WSS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12(1):1–20.
Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 2018;27(1):22–41.
pubmed: 28867301
Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–98.
pubmed: 30902670
Miller EF. Nutrition management strategies for nonalcoholic fatty liver disease: treatment and prevention. Clin Liver Dis. 2020;15(4):144.
Hadi HE, Vettor R, Rossato M. Vitamin E as a treatment for nonalcoholic fatty liver disease: reality or myth? Antioxidants. 2018;7(1):12.
pubmed: 29337849
pmcid: 5789322
Lin M, Zeng H, Deng G, Lei J, Li J. Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. Clin Res Hepatol Gastroenterol. 2021;45(3): 101530.
pubmed: 33272889
Schmölz L, Birringer M, Lorkowski S, Wallert M. Complexity of vitamin E metabolism. World J Biol Chem. 2016;7(1):14.
pubmed: 26981194
pmcid: 4768118
Civelek M, Podszun MC. Genetic factors associated with response to vitamin E treatment in NAFLD. Antioxidants. 2022;11(7): 1284.
pubmed: 35883775
pmcid: 9311784
Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–68.
pubmed: 21521847
pmcid: 3110082
Magosso E, Ansari MA, Gopalan Y, Shuaib IL, Wong J-W, Khan NAK, Abu Bakar MR, Ng B-H, Yuen K-H. Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial. Nutr J. 2013;12(1):1–8.
Murer SB, Aeberli I, Braegger CP, Gittermann M, Hersberger M, Leonard SW, Taylor AW, Traber MG, Zimmermann MB. Antioxidant supplements reduced oxidative stress and stabilized liver function tests but did not reduce inflammation in a randomized controlled trial in obese children and adolescents. J Nutr. 2014;144(2):193–201.
pubmed: 24353344
Nobili V, Alisi A, Mosca A, Crudele A, Zaffina S, Denaro M, Smeriglio A, Trombetta D. The antioxidant effects of hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease, in a clinical trial: a new treatment? Antioxid Redox Signal. 2019;31(2):127–33.
pubmed: 30588836
Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16(9):517–30.
pubmed: 31278377
Ferraioli G, Calcaterra V, Lissandrin R, Guazzotti M, Maiocchi L, Tinelli C, De Silvestri A, Regalbuto C, Pelizzo G, Larizza D. Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMC Gastroenterol. 2017;17(1):1–9.
Pervez MA, Khan DA, Ijaz A, Khan S. Effects of delta-tocotrienol supplementation on liver enzymes, inflammation, oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk J Gastroenterol. 2018;29(2):170.
pubmed: 29749323
pmcid: 6284694
Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J. 2019;95(1129):601–11.
pubmed: 31434683
Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Ther Adv Gastroenterol. 2020;13:1756284820974917.
Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine. 2017;96(17):e6770.
pubmed: 28445310
pmcid: 5413275
Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, Suman A, Orsak BK, Hecht J. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2019;42(8):1481–8.
pubmed: 31332029
Klein EA, Thompson IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, et al. Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.
pubmed: 21990298
pmcid: 4169010
Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ. Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(4):616–29 e626.
pubmed: 29913275
Wong SK, Chin K-Y, Ahmad F, Ima-Nirwana S. Regulation of inflammatory response and oxidative stress by tocotrienol in a rat model of non-alcoholic fatty liver disease. J Functional Foods. 2020;74: 104209.
Ziółkowska S, Kosmalski M, Kołodziej Ł, Jabłkowska A, Szemraj JZ, Pietras T, Jabłkowski M, Czarny PL. Single-nucleotide polymorphisms in base-excision repair-related genes involved in the risk of an occurrence of non-alcoholic fatty liver disease. Int J Mol Sci. 2023;24(14): 11307.
pubmed: 37511066
pmcid: 10379279
Trujillo M, Kharbanda A, Corley C, Simmons P, Allen AR. Tocotrienols as an anti-breast cancer agent. Antioxidants. 2021;10(9): 1383.
pubmed: 34573015
pmcid: 8472290
Zhao L, Kang I, Fang X, Wang W, Lee MA, Hollins RR, Marshall MR, Chung S. Gamma-tocotrienol attenuates high-fat diet-induced obesity and insulin resistance by inhibiting adipose inflammation and M1 macrophage recruitment. Int J Obes (Lond). 2015;39(3):438–46.
pubmed: 25042861
Pervez MA, Khan DA, Mirza SA, Slehria AUR, Nisar U, Aamir M. Comparison of delta-tocotrienol and alpha-tocopherol effects on hepatic steatosis and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized double-blind active-controlled trial. Complement Ther Med. 2022;70: 102866.
pubmed: 35933083
Matsunaga T, Shoji A, Gu N, Joo E, Li S, Adachi T, Yamazaki H, Yasuda K, Kondoh T, Tsuda K. γ-Tocotrienol attenuates TNF-α-induced changes in secretion and gene expression of MCP-1, IL-6 and adiponectin in 3T3-L1 adipocytes. Mol Med Rep. 2012;5(4):905–9.
pubmed: 22293775
pmcid: 3493080